Atossa Therapeutics (ATOS) announced that the U.S. FDA issued a “Study May Proceed” letter for the company’s study in metastatic breast cancer ...
Protein kinase inhibitors represent a major advance in cancer treatment due to their ability to target the specific kinases involved in tumor growth and survival. More than 80 small-molecule protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback